PARIS, France – October 06, 2025 – 10:00 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback